Skip to main content

Pain Medication and Opiate Addiction

  • Chapter
  • First Online:
Psychopharmacology Reconsidered

Abstract

Pain is a highly unpleasant and aversive human emotion. While it is elicited from stimulation of peripheral receptors via the spinothalamic tract to the thalamus in the brain, “top-down”: modulation from the cortex originating in social cues, self-confidence and such factors are also important in pain experience and behavior. The most potent pain medications are the opiates that stimulate several types of opiate receptor in the thalamus and elsewhere. The endogenous ligands of these receptors, enkephalins, are important neurotransmitters that are chemically short peptides. Opiates are highly effective in acute pain but come with a high potential for tolerance and addiction and are rarely indicated in chronic pain. Treatment of opiate addiction may involve maintenance with a partial agonist such as methadone or buprenorphine to substitute for abused opiates while blocking use of nonprescribed additional opiates. Opiate abuse side effects include overdose coma and death due to respiratory depression, and naloxone or naltrexone opiate antagonists able to reverse overdose should be available to first responders as well as to psychiatrists.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

eBook
USD 16.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Hardcover Book
USD 89.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Babu KM, Brent J, Juurlink DN. Prevention of opioid overdose. N Engl J Med. 2019;380(23):2246–55.

    Article  PubMed  Google Scholar 

  2. Haight BR, Learned SM, Laffont CM, Fudala PJ, Zhao Y, Garofalo AS, et al. Efficacy and safety of a monthly buprenorphine depot injection for opioid use disorder: a multicentre, randomised, double-blind, placebo-controlled, phase 3 trial. Lancet. 2019;393(10173):778–90.

    Article  CAS  PubMed  Google Scholar 

  3. McQueen K, Murphy-Oikonen J. Neonatal abstinence syndrome. N Engl J Med. 2016;375(25):2468–79.

    Article  PubMed  Google Scholar 

  4. Fairley M, Humphreys K, Joyce VR, Bounthavong M, Trafton J, Combs A, et al. Cost-effectiveness of treatments for opioid use disorder. JAMA Psychiatry. 2021;78(7):767–77.

    Article  PubMed  Google Scholar 

  5. Compton WM, Jones CM, Baldwin GT. Relationship between nonmedical prescription-opioid use and heroin use. N Engl J Med. 2016;374(2):154–63.

    Article  CAS  PubMed  Google Scholar 

  6. Schuckit MA. Treatment of opioid-use disorders. N Engl J Med. 2016;375(4):357–68.

    Article  PubMed  Google Scholar 

  7. Kalkman GA, Kramers C, van Dongen RT, van den Brink W, Schellekens A. Trends in use and misuse of opioids in The Netherlands: a retrospective, multi-source database study. Lancet Public Health. 2019;4(10):e498–505.

    Article  PubMed  Google Scholar 

  8. D'Onofrio G, O'Connor PG, Pantalon MV, Chawarski MC, Busch SH, Owens PH, et al. Emergency department-initiated buprenorphine/naloxone treatment for opioid dependence: a randomized clinical trial. JAMA. 2015;313(16):1636–44.

    Article  PubMed  PubMed Central  Google Scholar 

  9. Lott DC. Extended-release naltrexone: good but not a panacea. Lancet. 2018;391(10118):283–4.

    Article  PubMed  Google Scholar 

  10. Ortega R, Nozari A, Baker W, Surani S, Edwards M. Intranasal naloxone administration. N Engl J Med. 2021;384(12):e44.

    Article  PubMed  Google Scholar 

  11. Lee JD, Nunes EV Jr, Novo P, Bachrach K, Bailey GL, Bhatt S, et al. Comparative effectiveness of extended-release naltrexone versus buprenorphine-naloxone for opioid relapse prevention (X:BOT): a multicentre, open-label, randomised controlled trial. Lancet. 2018;391(10118):309–18.

    Article  CAS  PubMed  Google Scholar 

  12. Podolsky SH, Herzberg D, Greene JA. Preying on prescribers (and their patients) - pharmaceutical marketing, iatrogenic epidemics, and the Sackler legacy. N Engl J Med. 2019;380(19):1785–7.

    Article  PubMed  Google Scholar 

  13. Larance B, Dobbins T, Peacock A, Ali R, Bruno R, Lintzeris N, et al. The effect of a potentially tamper-resistant oxycodone formulation on opioid use and harm: main findings of the National Opioid Medications Abuse Deterrence (NOMAD) study. Lancet Psychiatry. 2018;5(2):155–66.

    Article  PubMed  Google Scholar 

  14. Davis CS. The Purdue pharma opioid settlement - accountability, or just the cost of doing business? N Engl J Med. 2021;384(2):97–9.

    Article  PubMed  Google Scholar 

  15. Cicero TJ, Ellis MS, Surratt HL. Effect of abuse-deterrent formulation of OxyContin. N Engl J Med. 2012;367(2):187–9.

    Article  CAS  PubMed  Google Scholar 

  16. Baker DW. History of the joint Commission’s pain standards: lessons for Today’s prescription opioid epidemic. JAMA. 2017;317(11):1117–8.

    Article  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Robert Haim Belmaker .

Rights and permissions

Reprints and permissions

Copyright information

© 2023 The Author(s), under exclusive license to Springer Nature Switzerland AG

About this chapter

Check for updates. Verify currency and authenticity via CrossMark

Cite this chapter

Belmaker, R.H., Lichtenberg, P. (2023). Pain Medication and Opiate Addiction. In: Psychopharmacology Reconsidered. Springer, Cham. https://doi.org/10.1007/978-3-031-40371-2_10

Download citation

  • DOI: https://doi.org/10.1007/978-3-031-40371-2_10

  • Published:

  • Publisher Name: Springer, Cham

  • Print ISBN: 978-3-031-40370-5

  • Online ISBN: 978-3-031-40371-2

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics